Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.

Cancer Research
Wendy L SeeRussell O Pieper

Abstract

Loss of neurofibromin 1 (NF1) leads to hyperactivation of RAS, which in turn signals through the RAF/MEK/ERK and phosphoinositide 3-kinase (PI3K)/mTOR pathways to regulate cell growth and survival. Because NF1-deficient acute myeloid leukemias are sensitive to MEK inhibitors, we investigated here whether NF1-deficient glioblastoma multiforme (GBM) would respond to MEK inhibition. In 19 GBM cell lines, we found that treatment with the clinically available MEK inhibitors PD0325901 or AZD6244 decreased levels of phospho-ERK, the downstream effector of MEK, regardless of NF1 status. However, growth inhibition occurred only in a subset of NF1-deficient cells, in association with decreased levels of cyclin D1, increased levels of p27, and G1 arrest. As a single agent, PD0325901 suppressed the growth of NF1-deficient, MEK inhibitor-sensitive cells in vivo as well. Mechanistically, NF1-deficient, MEK inhibitor-sensitive cells were dependent upon the RAF/MEK/ERK pathway for growth and did not activate the PI3K pathway as a mechanism of acquired resistance. Importantly, NF1-deficient cells intrinsically resistant to MEK inhibition were sensitized by the addition of the dual PI3K/mTOR inhibitor PI-103. Taken together, our findings indicat...Continue Reading

References

Mar 11, 1999·Current Opinion in Genetics & Development·R M Wolthuis, J L Bos
Jul 1, 1999·Genes & Development·C J Sherr, J M Roberts
Sep 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Philippe P RouxJohn Blenis
Dec 13, 2005·Nature Reviews. Cancer·Andreas G BaderPeter K Vogt
Aug 18, 2006·Nature Reviews. Cancer·David M Sabatini
Mar 27, 2007·Nature Reviews. Cancer·Suzanne SchubbertGideon Bollag
Jul 7, 2007·Cancer Cell·David A Guertin, David M Sabatini
Mar 5, 2008·Cancer Research·Balazs HegedusDavid H Gutmann
Aug 30, 2008·Current Biology : CB·Audrey CarrièrePhilippe P Roux
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Nov 21, 2008·Journal of Cell Science·Eric A Klein, Richard K Assoian
Jul 4, 2009·Cancer Cell·Lauren T McGillicuddyKaren Cichowski

❮ Previous
Next ❯

Citations

Feb 28, 2014·Journal of Carcinogenesis·Thanyanan Reungwetwattana, Grace Kho Dy
Feb 12, 2013·Biochimica Et Biophysica Acta·Michal Grzmil, Brian A Hemmings
May 23, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Gurvinder KaurAndrew T Parsa
Jan 11, 2013·The Journal of Investigative Dermatology·David E ReussAndreas von Deimling
Mar 31, 2015·European Journal of Nuclear Medicine and Molecular Imaging·A Lo DicoL Ottobrini
Jun 30, 2015·PloS One·Stephanie StröbeleKlaus-Michael Debatin
Jul 15, 2016·Journal of Medicinal Chemistry·Timothy P Heffron
Jan 4, 2017·The American Journal of Dermatopathology·J Andrew CarlsonJeffrey S Ross
Dec 17, 2017·Journal of Child Neurology·Cynthia J Campen, David H Gutmann
Sep 12, 2018·Pharmacogenomics·Jacob S YoungNicholas Butowski
Oct 6, 2018·SLAS Technology·Kelli M WilsonGregory J Riggins
Apr 29, 2018·Journal of Neuroscience Research·Morgan E Freret, David H Gutmann
Oct 23, 2018·Journal of Neurochemistry·Pouria KhaniHamed Mirzaei
Jul 1, 2015·Neurosurgery·Patrick J CiminoSonika Dahiya
Jan 13, 2017·Topics in Magnetic Resonance Imaging : TMRI·Rebecca A Harrison, John F de Groot
Jul 1, 2020·Neuropathology and Applied Neurobiology·J S NixF J Rodriguez
Apr 5, 2017·Journal of the National Cancer Institute·Carl E AllenUNKNOWN Pediatric MATCH Target and Agent Prioritization Committee
Apr 1, 2019·Brain Tumor Pathology·Kensuke TateishiTetsuya Yamamoto
Jul 16, 2014·Oncotarget·Yoon-Sim YapDavid F Callen
Oct 20, 2017·Pediatric Blood & Cancer·Soumen KhatuaRoger J Packer
Apr 10, 2019·Acta Neuropathologica·J Stephen NixFausto J Rodriguez
Feb 12, 2017·BMC Cancer·Stephen ShannonRamsey A Foty
Jul 1, 2017·Molecular Neurobiology·Aubin MoutalRajesh Khanna
Jul 10, 2020·Neuro-oncology Advances·Tobias KesslerAntje Wick
Oct 30, 2018·Frontiers in Oncology·Euphemia Y LeungBruce C Baguley
Nov 26, 2020·Neuro-oncology Advances·Karisa C SchreckChristine A Pratilas
Jul 25, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Douglas I LinJulia A Elvin
Sep 11, 2021·Scientific Reports·Mark M ZakiWenya Linda Bi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.